ArticleMaterials today. Bio2025
Stepwise targeting hyaluronic acid-based polymeric prodrug for acute kidney injury and prevents its progression to chronic kidney disease.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineered naringenin-loaded nanoscale coordination polymers for targeted treatment of acute kidney injury.Materials today. Bio · 2026Article
- Layered double hydroxide nanocarriers loaded with butylphthalide attenuate the AKI-CKD transition by regulating mitophagy.Materials today. Bio · 2026Article
- Recent advances in stimuli-responsive nanomaterials for the treatment of acute kidney injury.Journal of nanobiotechnology · 2026Review
- Chitosan Oligosaccharide-Functionalized Ruthenium-Curcumin Nanodots for Targeted Therapy of Acute Kidney Injury.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is characterized by a sudden decline in kidney function, often due to ischemia-reperfusion or nephrotoxic drugs. A key factor in AKI development is mitochondrial dysfunction, which disrupts energy and oxygen supply, increases ROS generation, and triggers inflammation. Addressing AKI through mitochondrial targeting remains challenging. Melatonin (MLT), a hormone secreted by the pineal gland, shows promise in AKI treatment. To enhance site-specific antioxidative efficacy, triphenylphosphonium-hyaluronic acid (TPP-HA), targeting CD44 receptors and mitochondria, was synthesized and linked to MLT via a cleavable linker, creating TPP-HA-TK-MLT (THTM). THTM improved MLT targeting in renal tubular epithelial cells through CD44 receptors and enhanced mitochondrial distribution via TPP. This effectively suppressed mitochondrial ROS under pathological conditions, ameliorated mitochondrial permeability and swelling, and increased resistance to stimuli such as ischemia-reperfusion injury or nephrotoxic drugs, reducing cell apoptosis. Moreover, THTM significantly reduced the progression of folic acid-induced kidney injury to chronic kidney disease, demonstrating its potential to lower the risk of chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.